Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Net Issuance of Preferred Stock : HK$0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Shenzhen Hepalink Pharmaceutical Group Co's net issuance of preferred for the three months ended in Mar. 2024 was HK$0 Mil. The number is 0, which means that Shenzhen Hepalink Pharmaceutical Group Co has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Shenzhen Hepalink Pharmaceutical Group Co's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was HK$0 Mil.

Shenzhen Hepalink Pharmaceutical Group Co Net Issuance of Preferred Stock Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Net Issuance of Preferred Stock Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Shenzhen Hepalink Pharmaceutical Group Co Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Shenzhen Hepalink Pharmaceutical Group Co Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Net Issuance of Preferred Stock

Traded in Other Exchanges

002399:China

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Executives

Orbimed Capital Llc	2102 Investment manager
Morgan Stanley & Co. International Plc	2105 Underwriter
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Avict Global Holdings Limited	2101 Beneficial owner
Worldwide Healthcare Trust Plc	2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Headlines

No Headlines